Mr. Charaf Eddine Kadri, General Director of Sandoz Vietnam shared: In the first year of independent operations, Sandoz Vietnam achieved extremely significant growth. Not only maintaining the group's global commitment, we also strive to understand and solve the diverse needs of the domestic healthcare industry. From expanding access to high-quality healthcare for patients, to strengthening strategic cooperation and contributing to overcoming many outstanding issues in the national healthcare system, Sandoz Vietnam has been laying a solid foundation for the future. We are proud of what we have achieved, and committed to joining hands to make further efforts with our partners.
In 2024, Sandoz signed a memorandum of understanding with Ho Chi Minh City Oncology Hospital, K. Sandoz Hospital plans to organize another training course at Cho Ray Hospital in August, with more than 150 medical staff participating.
These initiatives contribute to raising awareness of Rituximab, a similar biological drug of Sandoz used in the treatment of non- Hodgkin's U lymphoph nodes. By the end of 2024, more than 2,000 patients will have access to the product, an increase of 48% compared to the previous year.
